Beubler E, Badhri P
Department of Experimental and Clinical Pharmacology, University of Graz, Austria.
J Pharm Pharmacol. 1990 Oct;42(10):689-92. doi: 10.1111/j.2042-7158.1990.tb06560.x.
The antidiarrhoeal effect of loperamide is caused by its antimotility and antisecretory properties. In-vivo experiments in the rat jejunum and colon have been performed to compare the antisecretory effect of loperamide with the effect of its prodrug, loperamide oxide. Both loperamide and loperamide oxide administered intraluminally, equally and dose dependently (2 to 250 micrograms mL-1) reduced PGE2-induced net fluid secretion (32 ng min-1 i.a.) in the jejunum and colon. The antisecretory effect of both drugs is blocked by naloxone (1 mg kg-1 s.c.). It is concluded that loperamide oxide administered intraluminally is reduced to loperamide and has the same antisecretory potency as loperamide in jejunum and colon. The effect appears to be mediated via opiate receptors. The observation that loperamide cannot be detected in the colonic lumen two h after oral administration suggests that the drug is delivered from the blood stream to the site of action after absorption in the small intestine.
洛哌丁胺的止泻作用源于其抗蠕动和抗分泌特性。已在大鼠空肠和结肠中进行体内实验,以比较洛哌丁胺与其前体药物氧化洛哌丁胺的抗分泌作用。腔内给予洛哌丁胺和氧化洛哌丁胺,二者均能同等且剂量依赖性地(2至250微克/毫升)减少空肠和结肠中前列腺素E2诱导的净液体分泌(32纳克/分钟,经肠内给予)。两种药物的抗分泌作用均被纳洛酮(1毫克/千克,皮下注射)阻断。得出的结论是,腔内给予的氧化洛哌丁胺被还原为洛哌丁胺,且在空肠和结肠中具有与洛哌丁胺相同的抗分泌效力。该作用似乎是通过阿片受体介导的。口服给药两小时后在结肠腔内未检测到洛哌丁胺这一观察结果表明,该药物在小肠吸收后从血流输送至作用部位。